Trust Co. of Toledo NA OH Purchases 10,713 Shares of Pfizer Inc. (NYSE:PFE)

Trust Co. of Toledo NA OH increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 154,346 shares of the biopharmaceutical company's stock after buying an additional 10,713 shares during the period. Trust Co. of Toledo NA OH's holdings in Pfizer were worth $3,911,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Norges Bank bought a new stake in Pfizer in the fourth quarter valued at approximately $2,328,986,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the period. Starboard Value LP bought a new stake in shares of Pfizer in the 4th quarter valued at $407,730,000. Raymond James Financial Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at $274,694,000. Finally, Assenagon Asset Management S.A. raised its stake in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after buying an additional 7,581,030 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on PFE shares. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group boosted their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Down 1.3%

Pfizer stock traded down $0.33 during mid-day trading on Friday, reaching $24.51. The company's stock had a trading volume of 46,354,360 shares, compared to its average volume of 41,209,115. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The business's 50 day simple moving average is $23.06 and its 200 day simple moving average is $24.95. The company has a market capitalization of $139.35 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the company earned $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. The ex-dividend date was Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.